Are there exceptions when Subutex and Suboxone or approved generic versions of these products may be administered by a practitioner without the DATA 2000 waiver?
Under the Narcotic Addiction Treatment Act of 1974, all practitioners who use narcotic drugs for treating opiate addiction must obtain a separate registration under 21 U.S.C. Section 823(g)(1) or a DATA 2000 Waiver under 21 U.S.C. Section 823(g)(2). However, according to the Drug Enforcement Administration (DEA), an exception to the registration requirement, known as the “three-day rule” (Title 21, Code of Federal Regulations, Part 1306.07(b)), allows a practitioner who is not separately registered as a narcotic treatment program or certified as a “waivered DATA 2000 physician,” to administer (but not prescribe) narcotic drugs to a patient for the purpose of relieving acute withdrawal symptoms while arranging for the patient’s referral for treatment, under the following conditions: 1) not more than one day’s medication may be administered or given to a patient at one time; 2) this treatment may not be carried out for more than 72 hours; and 3) this 72-hour period cannot be renewed or e
Related Questions
- Are there exceptions when Subutex and Suboxone or approved generic versions of these products may be administered by a practitioner without the DATA 2000 waiver?
- Can Subutex® or Suboxone® or approved generic versions of these products be prescribed for conditions other than opioid addiction, e.g., pain control?
- Are there exceptions when Subutex and Suboxone may be administered by a practitioner without the DATA 2000 waiver?
